Manufacturing
Pipeline
PIPELINE
At MUP, we have continued to optimize our product portfolio, prioritizing products with the greatest promise and rationalizing those that have become less attractive. New product introductions have also enhanced our portfolio in 2020, as we launched more than 200 products in different dosage forms and strengths globally.
We have large and exciting pipelines for all of our businesses, with approximately 70 products in different dosage forms and strengths pending regulatory approval and around 50 in our development pipeline.
Highly innovative technologies are applied to support the regional health care market with high-quality products.
Our pipeline of 70 new molecules covers a broad range of diseases.
1 BIOSIMILARS
1 ANTI-PARKINSON
1 METABOLIC PRODUCTS
2 DIABETES
3 ANALGESICS / MIGRAIN
3 NASAL DECONG/ANTI INFECT
4 SYSTEMIC ANTIBACTERIALS
4 DERMATOLOGY
4 INTRAVENOUS SOLUTIONS
6 OPHTHALMOLOGICAL
6 VITAMINS and Minerals
27 OTHERS
Our pipeline of 70 new molecules covers a broad range of diseases.
1 BIOSIMILARS
1 ANTI-PARKINSON
1 METABOLIC PRODUCTS
2 DIABETES
3 ANALGESICS / MIGRAIN
3 NASAL DECONG/ANTI INFECT
4 SYSTEMIC ANTIBACTERIALS
4 DERMATOLOGY
4 INTRAVENOUS SOLUTIONS
6 OPHTHALMOLOGICAL
6 VITAMINS and Minerals
27 OTHERS
ADDING CAPACITY
With strong demand for our currently marketed products and a sizable pipeline, we are investing to ensure we have the capacity to continue delivering as we grow. In particular, we have significantly increased our insulin cartridges, purchasing high-quality machinery and equipment from the Robert Bosch GmbH for our sites in MUP Tech (October, Egypt).
This investment will enable us to quickly and efficiently execute our medium to long-term product launch plans and expand across all of our markets. In Addition to biological manufacturing, we are developing our production capability for soft gelatin capsules, Prefilled syringes, Ophthalmic eye drops and large volume/small volume solutions.
PATENCY
MUP gained several patents in the area of pharmaceutical drug formulation
BIOVIT 12 DEPOT
The invention is the production on a commercial scale of a stable pharmaceutical drug product for I.M injection, in which folic acid, Vit B12 and Vit B6 are combined in one ampoule (Biovit 12- Depot ampoule 2 ml), which leads to lower manufacturing cost and avoid limited compliance for use.
CELECOXIB
The invention describes novel compositions of celecoxib in the form of transparent liquid concentrates. The compositions hold the drug in a solubilized form on dilution with water or alternatively form a nano-suspension with a particle size much less than 200 nm leading to enhanced absorption.
RAPIFEN
This innovation considers a pharmaceutical preparation in the form of transparent microemulsion preconcentrate for Ibuprofen ready to be filled into a soft gelatin capsule containing medium-chain fatty acids triglycerides and non- ionic surfactants and/or mono- or di- or tri hydroxyl alcohols and water.